Amarantus Investor Info
Post# of 30028
Posted On: 01/01/2015 10:22:59 AM
Amarantus Investor Information, News & Events
Links
Amarantus Website:
http://www.amarantus.com/
Amarantus News and Events:
http://ir.amarantus.com/company-news
Amarantus Chairman's Blog:
http://www.thechairmansblog.com/amarantus-bioscience/blogs/
Amarantus SEC Filings:
http://www.sec.gov/cgi-bin/browse-edgar?CIK=0...getcompany
Corporate Presentations/Webcasts/Transcripts
Dec. 2, 2014 - LD Micro VII: Main Event -
Presentation - http://content.stockpr.com/amarantus/media/3b...121792.pdf
Webcast - http://wsw.com/webcast/ldmicro7/ambs
Nov. 18, 2014 - Business Update Conference Call - https://www.webcaster4.com/Webcast/Page/759/6538
Oct. 7, 2014 - Targeting Ocular Disorders Conference
http://content.stockpr.com/amarantus/media/aa...64655e.pdf
Sept. 12, 2014 - Aegis Capital Healthcare and Technology Conference
Presentation - http://a.eqcdn.com/amarantus/media/096237eb54...609f65.pdf
Webcast - http://wsw.com/webcast/aegis/ambs/
April 24, 2014 - Conference Call
Transcript - http://ir.amarantus.com/all-sec-filings/conte...025532.pdf
Company News
Diagnostics
Lympro - Total Market opportunity estimated at $3B
Dec. 29, 2014 - Amarantus to Present LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) at Biotech Showcase 2015 Conference on January 14, 2015
Dec. 22, 2014 - Amarantus Commences Launch of Proprietary Alzheimer's Blood Diagnostic LymPro Test(R) to Pharmaceutical Industry for Use in Clinical Trials
Nov. 20, 2014 - Amarantus Completes Enrollment of Expanded LP-002 Study of Alzheimer's Blood Diagnostic LymPro Test(R) to Assess Predictive Value in Early-Stage Disease
Oct. 9, 2014 - Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test
Sept. 12, 2014 - Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test
Sept. 2, 2014 - Amarantus Initiates CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
Aug. 1, 2014 - Amarantus Announces Positive Top-Line Interim Clinical Data for Alzheimer's Blood Diagnostic LymPro Test
July 15, 2014 -Amarantus Announces Positive Clinical Performance and 7-Year Longitudinal Data Poster Presentations for LymPro Test at AAIC 2014
May 5, 2014 - Amarantus Acquires Additional Rights to LymPro Test From Memory Dx
Jan. 29, 2014 - Amarantus Establishes LymPro Research Collaboration With Boston University School of Medicine
Oct. 14, 2013 - Amarantus Announces Positive Analytical Performance Data for LymPro Test(R) for Alzheimer's Disease
Additional Diagnostics News
Dec. 22, 2014 - "Moving forward, we expect to announce additional significant news in the coming weeks regarding LymPro, as well as pending additions to our diagnostics division to buttress this business unit for a potential spin-off into a standalone entity."
Nov. 18, 2014 - AMBS Near-Term Milestone: Preparation for potential spin-out of diagnostics division (potential stock dividend to shareholders)
Oct. 27, 2014 - "We are actively evaluating additional complementary late-stage neurology-focused diagnostic assets that would bolster our diagnostic division and make for a successful ‘spin-out’ while concurrently returning value to our shareholders. We believe we will be able to execute on this strategy in the near-term."
Therapeutics
Retinal - $1B+ market opportunity
Dec. 23, 2014 - Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
Dec. 19, 2014 - Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
Nov. 25, 2014 - Amarantus Announces Positive Preclinical Data on the Effects of MANF on Vision in a Model of Retinitis Pigmentosa
Oct. 16, 2014- Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
Oct. 7, 2014 - Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference
Oct. 1 2014 - Amarantus enters into a sponsored research agreement with the University of Miami on the use of MANF in retinal disorders
Sept. 9, 2014 - Amarantus Announces Positive MANF Ocular Toxicology Data
Aug. 26, 2014 - Amarantus enters into a master services agreement with ICON Clinical Research Limited pursuant to which the Company retained ICON to provide the Company with certain central laboratory services in connection with certain research studies
Aug. 15, 2014 - Amarantus to License Intellectual Property From Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
Aug. 11, 2014 - Company Acquires Exclusive Option to License Undisclosed MANF IP from Buck Institute for Research on Aging
Aug. 11, 2014 - Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
July 2, 2014 - Amarantus Announces Positive Interim Toxicology Data for MANF in Retinitis Pigmentosa
March 3, 2014 - Amarantus Outlines MANF Research Collaboration Strategy
Dec. 3, 2013 - Amarantus Obtains Exclusive Option to License University of Miami Bascom Palmer Eye Institute's Intellectual Property for the Treatment of Retinal Diseases Using MANF and CDNF
Aug. 12, 2013 - Amarantus Announces Positive Orphan Data for MANF in Retinitis Pigmentosa
Eltoprazine - Potential sales worldwide: $1B+
Sept. 29, 2014 - Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial
Sept. 17, 2014 - Amarantus Provides Program Update on Phase 2b Eltoprazine for Parkinson's Disease and Adult ADHD
Jan. 14, 2014 - Amarantus In-Licenses Levadopa-Induced Dyskinesia Phase 2b-Ready Eltoprazine From PGI Drug Discovery
February 4, 2014 - Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD
Wolfram
June 20, 2014 - Amarantus entered into research collaboration with the Washington University School of Medicine
Dec. 18, 2013 - Amarantus Licenses MANF-Related Wolfram's and Diabetes Therapeutic and Diagnostic Intellectual Property From University of Massachusetts Medical School
Otology
March 6, 2014 - Amarantus Acquires Exclusive Option to License Intellectual Property for Use of MANF and CDNF to Treat Antibiotic-Induced Ototoxicity
Alzheimer Therapeutic
Aug. 1, 2014 - Amarantus BioSciences, Inc. Acquires Exclusive Option To License Alzheimer's Therapeutic IP Of Dr. Thomas Arendt From University of Leipzig
July 1, 2014 - Amarantus Independently Confirms Published Chinese Positive MANF Tau Phosphorylation Data for Alzheimer's Disease
May 1, 2014 - Amarantus Announces Positive Independent Peer-Reviewed Preclinical Data for MANF in Alzheimer's and Diabetes
Regenerative Medicine
ESS-W - Market opportunity in US: $500M+
Dec. 12, 2014 - Phase 2 Clinical Trial initiating in Q2/2015
Nov. 17, 2014 - Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
Discovery
PhenoGuard
April 28, 2014 - Amarantus CSO to Present on PhenoGuard Data at Astrocytes in Health and Neurodegenerative Disease in London - To date, we have screened 37 of our library of 88 astrocyte cell lines. All 37 ACMs screened to date secrete neuroprotective molecules, and several meet the criteria for further analysis as potential drug candidates for PD.
Nov. 12th, 2013 - We expect to be in a position to start collaborating on this project in early 2014 having expanded our PhenoGuard cell line library to 88 cell lines from four distinct brain regions associated with Parkinson’s, Alzheimer’s, Clinical Depression and Huntington’s disease.
Company
People
Dec. 11, 2014 - Amarantus Appoints Elise Brownell, Ph.D., as Senior Vice President of Operations and Project Management
Dec. 8, 2014 - Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors
Oct. 20, 2014 - Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees
Aug. 29, 2014 - Amarantus Appoints Iain Ross to Board of Directors
July 28, 2014 - Amarantus Appoints Donald D. Huffman to Board of Directors
April 8, 2014 - Amarantus Appoints Dr. Charlotte Keywood Chief Medical Officer of Its Therapeutics Division
April 1, 2014 - Amarantus Appoints Robert Farrell, J.D. as Chief Financial Officer
March 31, 2014 - Amarantus Appoints Dr. Louis Kirby to Board of Advisors
Feb. 24, 2014 - Amarantus Strengthens Management Team With Key Additions in Business Development and Regulatory Affairs (Kerry Segal as Head of Business Development and Tiffini Clark as Head of Regulatory Affairs)
Nov. 6, 2013 - Amarantus Appoints David A. Lowe, PhD to Board of Directors
Sept. 13, 2013 - Amarantus Appoints F. Randall Grimes, MBA as Director of Sponsored Research
Sept. 3, 2013 - Amarantus Appoints Dr. Colin Bier to Advisory Board for LymPro Commercialization
Place
Aug. 2014 - Amarantus relocates its priciple offices to larger space at 655 Montgomery Street IN San Francisco, California (5,700 sq.ft.) while continuing to lease office and laboratory space at Janssen Labs
Oct. 30, 2013 - Amarantus Relocates Headquarters to Janssen Labs @QB3 Incubator in San Francisco
May 6, 2014 - Amarantus Establishes Office in Geneva, Switzerland
Funding
Dec. 19, 2014 - Amarantus Announces Second Closing of Series E Preferred Financing
Nov. 10, 2014 - Amarantus Reports Third Quarter 2014 Financial Results and Enters Into Strategic Preferred Financing
March 10, 2014 - Amarantus Closes Warrant Solicitation; Enters Into $20 Million Purchase Agreement With Lincoln Park Capital Fund, LLC
Feb. 18, 2014 - Amarantus Bioscience Holdings Announces $3M Solicitation of Previously Issued Warrants
Conferences
Jan. 28, 2015 - #C4CT Concussion Awareness Summit in Scottsdale, Arizona
Jan. 14, 2015 - Biotech Showcase 2015 Conference in San Francisco, CA
Dec. 2, 2014 - LD Micro Main Event VII Investor Conference in Los Angeles, California
Oct. 6, 2014 - Targeting Ocular Disorders Conference in Boston, MA
Oct. 1, 2014 - Sachs Associates 14th Annual Biotech in Europe Forum for Global Partnering and Investment in Basel, Switzerland
Sept. 8, 2014 - First Annual Zacks Healthcare Meetup in New York City
Sept. 9, 2014 - 16th Annual Rodman & Renshaw Healthcare Conference in New York City
Sept. 11, 2014 - Aegis Capital Healthcare and Technology Conference in Las Vegas, Nevada
July 31, 2014 - 3rd Alzheimer's Focused #C4CT Summit in United Nations, New York City
June 26, 2014 - 2014 BIO International Convention in San Diego, California
May 29, 2014 - 3rd Annual Marcum MicroCap Conference at the Grand Hyatt Hotel in New York
May 12, 2014 - 15th Annual B. Riley & Co. Investor Conference in Santa Monica, CA
May 7, 2014 - Cavendish Global Health Impact Forum
Additional Information & Publications
US National Library of Medicine National Institutes of Health MANF Search:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Mese...hic+factor
Additional Interviews
SNNLive - Amarantus BioScience Holdings, Inc.
Dec. 2, 2014 - https://www.youtube.com/watch?v=R0pSOiId83c
All - https://www.youtube.com/user/SNNWire/search?q...ommissiong
February 19, 2014 - Gerald Commissiong CEO of Amarantus Bioscience Interview on Clear Channel "The Traders Network Show”
https://www.youtube.com/watch?v=bRu-PciMUqg
Links
Amarantus Website:
http://www.amarantus.com/
Amarantus News and Events:
http://ir.amarantus.com/company-news
Amarantus Chairman's Blog:
http://www.thechairmansblog.com/amarantus-bioscience/blogs/
Amarantus SEC Filings:
http://www.sec.gov/cgi-bin/browse-edgar?CIK=0...getcompany
Corporate Presentations/Webcasts/Transcripts
Dec. 2, 2014 - LD Micro VII: Main Event -
Presentation - http://content.stockpr.com/amarantus/media/3b...121792.pdf
Webcast - http://wsw.com/webcast/ldmicro7/ambs
Nov. 18, 2014 - Business Update Conference Call - https://www.webcaster4.com/Webcast/Page/759/6538
Oct. 7, 2014 - Targeting Ocular Disorders Conference
http://content.stockpr.com/amarantus/media/aa...64655e.pdf
Sept. 12, 2014 - Aegis Capital Healthcare and Technology Conference
Presentation - http://a.eqcdn.com/amarantus/media/096237eb54...609f65.pdf
Webcast - http://wsw.com/webcast/aegis/ambs/
April 24, 2014 - Conference Call
Transcript - http://ir.amarantus.com/all-sec-filings/conte...025532.pdf
Company News
Diagnostics
Lympro - Total Market opportunity estimated at $3B
Dec. 29, 2014 - Amarantus to Present LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) at Biotech Showcase 2015 Conference on January 14, 2015
Dec. 22, 2014 - Amarantus Commences Launch of Proprietary Alzheimer's Blood Diagnostic LymPro Test(R) to Pharmaceutical Industry for Use in Clinical Trials
Nov. 20, 2014 - Amarantus Completes Enrollment of Expanded LP-002 Study of Alzheimer's Blood Diagnostic LymPro Test(R) to Assess Predictive Value in Early-Stage Disease
Oct. 9, 2014 - Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test
Sept. 12, 2014 - Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test
Sept. 2, 2014 - Amarantus Initiates CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
Aug. 1, 2014 - Amarantus Announces Positive Top-Line Interim Clinical Data for Alzheimer's Blood Diagnostic LymPro Test
July 15, 2014 -Amarantus Announces Positive Clinical Performance and 7-Year Longitudinal Data Poster Presentations for LymPro Test at AAIC 2014
May 5, 2014 - Amarantus Acquires Additional Rights to LymPro Test From Memory Dx
Jan. 29, 2014 - Amarantus Establishes LymPro Research Collaboration With Boston University School of Medicine
Oct. 14, 2013 - Amarantus Announces Positive Analytical Performance Data for LymPro Test(R) for Alzheimer's Disease
Additional Diagnostics News
Dec. 22, 2014 - "Moving forward, we expect to announce additional significant news in the coming weeks regarding LymPro, as well as pending additions to our diagnostics division to buttress this business unit for a potential spin-off into a standalone entity."
Nov. 18, 2014 - AMBS Near-Term Milestone: Preparation for potential spin-out of diagnostics division (potential stock dividend to shareholders)
Oct. 27, 2014 - "We are actively evaluating additional complementary late-stage neurology-focused diagnostic assets that would bolster our diagnostic division and make for a successful ‘spin-out’ while concurrently returning value to our shareholders. We believe we will be able to execute on this strategy in the near-term."
Therapeutics
Retinal - $1B+ market opportunity
Dec. 23, 2014 - Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
Dec. 19, 2014 - Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
Nov. 25, 2014 - Amarantus Announces Positive Preclinical Data on the Effects of MANF on Vision in a Model of Retinitis Pigmentosa
Oct. 16, 2014- Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
Oct. 7, 2014 - Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference
Oct. 1 2014 - Amarantus enters into a sponsored research agreement with the University of Miami on the use of MANF in retinal disorders
Sept. 9, 2014 - Amarantus Announces Positive MANF Ocular Toxicology Data
Aug. 26, 2014 - Amarantus enters into a master services agreement with ICON Clinical Research Limited pursuant to which the Company retained ICON to provide the Company with certain central laboratory services in connection with certain research studies
Aug. 15, 2014 - Amarantus to License Intellectual Property From Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
Aug. 11, 2014 - Company Acquires Exclusive Option to License Undisclosed MANF IP from Buck Institute for Research on Aging
Aug. 11, 2014 - Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
July 2, 2014 - Amarantus Announces Positive Interim Toxicology Data for MANF in Retinitis Pigmentosa
March 3, 2014 - Amarantus Outlines MANF Research Collaboration Strategy
Dec. 3, 2013 - Amarantus Obtains Exclusive Option to License University of Miami Bascom Palmer Eye Institute's Intellectual Property for the Treatment of Retinal Diseases Using MANF and CDNF
Aug. 12, 2013 - Amarantus Announces Positive Orphan Data for MANF in Retinitis Pigmentosa
Eltoprazine - Potential sales worldwide: $1B+
Sept. 29, 2014 - Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial
Sept. 17, 2014 - Amarantus Provides Program Update on Phase 2b Eltoprazine for Parkinson's Disease and Adult ADHD
Jan. 14, 2014 - Amarantus In-Licenses Levadopa-Induced Dyskinesia Phase 2b-Ready Eltoprazine From PGI Drug Discovery
February 4, 2014 - Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD
Wolfram
June 20, 2014 - Amarantus entered into research collaboration with the Washington University School of Medicine
Dec. 18, 2013 - Amarantus Licenses MANF-Related Wolfram's and Diabetes Therapeutic and Diagnostic Intellectual Property From University of Massachusetts Medical School
Otology
March 6, 2014 - Amarantus Acquires Exclusive Option to License Intellectual Property for Use of MANF and CDNF to Treat Antibiotic-Induced Ototoxicity
Alzheimer Therapeutic
Aug. 1, 2014 - Amarantus BioSciences, Inc. Acquires Exclusive Option To License Alzheimer's Therapeutic IP Of Dr. Thomas Arendt From University of Leipzig
July 1, 2014 - Amarantus Independently Confirms Published Chinese Positive MANF Tau Phosphorylation Data for Alzheimer's Disease
May 1, 2014 - Amarantus Announces Positive Independent Peer-Reviewed Preclinical Data for MANF in Alzheimer's and Diabetes
Regenerative Medicine
ESS-W - Market opportunity in US: $500M+
Dec. 12, 2014 - Phase 2 Clinical Trial initiating in Q2/2015
Nov. 17, 2014 - Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
Discovery
PhenoGuard
April 28, 2014 - Amarantus CSO to Present on PhenoGuard Data at Astrocytes in Health and Neurodegenerative Disease in London - To date, we have screened 37 of our library of 88 astrocyte cell lines. All 37 ACMs screened to date secrete neuroprotective molecules, and several meet the criteria for further analysis as potential drug candidates for PD.
Nov. 12th, 2013 - We expect to be in a position to start collaborating on this project in early 2014 having expanded our PhenoGuard cell line library to 88 cell lines from four distinct brain regions associated with Parkinson’s, Alzheimer’s, Clinical Depression and Huntington’s disease.
Company
People
Dec. 11, 2014 - Amarantus Appoints Elise Brownell, Ph.D., as Senior Vice President of Operations and Project Management
Dec. 8, 2014 - Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors
Oct. 20, 2014 - Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees
Aug. 29, 2014 - Amarantus Appoints Iain Ross to Board of Directors
July 28, 2014 - Amarantus Appoints Donald D. Huffman to Board of Directors
April 8, 2014 - Amarantus Appoints Dr. Charlotte Keywood Chief Medical Officer of Its Therapeutics Division
April 1, 2014 - Amarantus Appoints Robert Farrell, J.D. as Chief Financial Officer
March 31, 2014 - Amarantus Appoints Dr. Louis Kirby to Board of Advisors
Feb. 24, 2014 - Amarantus Strengthens Management Team With Key Additions in Business Development and Regulatory Affairs (Kerry Segal as Head of Business Development and Tiffini Clark as Head of Regulatory Affairs)
Nov. 6, 2013 - Amarantus Appoints David A. Lowe, PhD to Board of Directors
Sept. 13, 2013 - Amarantus Appoints F. Randall Grimes, MBA as Director of Sponsored Research
Sept. 3, 2013 - Amarantus Appoints Dr. Colin Bier to Advisory Board for LymPro Commercialization
Place
Aug. 2014 - Amarantus relocates its priciple offices to larger space at 655 Montgomery Street IN San Francisco, California (5,700 sq.ft.) while continuing to lease office and laboratory space at Janssen Labs
Oct. 30, 2013 - Amarantus Relocates Headquarters to Janssen Labs @QB3 Incubator in San Francisco
May 6, 2014 - Amarantus Establishes Office in Geneva, Switzerland
Funding
Dec. 19, 2014 - Amarantus Announces Second Closing of Series E Preferred Financing
Nov. 10, 2014 - Amarantus Reports Third Quarter 2014 Financial Results and Enters Into Strategic Preferred Financing
March 10, 2014 - Amarantus Closes Warrant Solicitation; Enters Into $20 Million Purchase Agreement With Lincoln Park Capital Fund, LLC
Feb. 18, 2014 - Amarantus Bioscience Holdings Announces $3M Solicitation of Previously Issued Warrants
Conferences
Jan. 28, 2015 - #C4CT Concussion Awareness Summit in Scottsdale, Arizona
Jan. 14, 2015 - Biotech Showcase 2015 Conference in San Francisco, CA
Dec. 2, 2014 - LD Micro Main Event VII Investor Conference in Los Angeles, California
Oct. 6, 2014 - Targeting Ocular Disorders Conference in Boston, MA
Oct. 1, 2014 - Sachs Associates 14th Annual Biotech in Europe Forum for Global Partnering and Investment in Basel, Switzerland
Sept. 8, 2014 - First Annual Zacks Healthcare Meetup in New York City
Sept. 9, 2014 - 16th Annual Rodman & Renshaw Healthcare Conference in New York City
Sept. 11, 2014 - Aegis Capital Healthcare and Technology Conference in Las Vegas, Nevada
July 31, 2014 - 3rd Alzheimer's Focused #C4CT Summit in United Nations, New York City
June 26, 2014 - 2014 BIO International Convention in San Diego, California
May 29, 2014 - 3rd Annual Marcum MicroCap Conference at the Grand Hyatt Hotel in New York
May 12, 2014 - 15th Annual B. Riley & Co. Investor Conference in Santa Monica, CA
May 7, 2014 - Cavendish Global Health Impact Forum
Additional Information & Publications
US National Library of Medicine National Institutes of Health MANF Search:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Mese...hic+factor
Additional Interviews
SNNLive - Amarantus BioScience Holdings, Inc.
Dec. 2, 2014 - https://www.youtube.com/watch?v=R0pSOiId83c
All - https://www.youtube.com/user/SNNWire/search?q...ommissiong
February 19, 2014 - Gerald Commissiong CEO of Amarantus Bioscience Interview on Clear Channel "The Traders Network Show”
https://www.youtube.com/watch?v=bRu-PciMUqg
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼